Karuna Therapeutics, Inc. KRTX
329.83 0.00 (+0.00%)
At closeMar 15, 2024, 4:00 PM EDT
329.75 Day range 329.97
52-week range unavailable
News
zacks.com Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.
businesswire.com Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with…
businesswire.com KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna…
zacks.com Bullish Continuation in '24? 3 Market Areas to Watch Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.
benzinga.com 5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
cnbc.com Cramer names biopharma companies to watch as industry mergers start to pile up CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
businesswire.com KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna…
zacks.com Yes Virginia, There Is a Santa Claus Rally The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.
zacks.com Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.
247wallst.com Nano Dimension Buys Stratasys, Bristol Myers's Shopping Spree, Apple Gets a ‘No' The holiday shopping season isn't over yet. A 3-D printing company and a major pharmaceuticals maker announced post-Christmas acquisitions Tuesday morning.
benzinga.com Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
invezz.com Bristol-Myers buying Karuna signals a biotech boom ahead: Jefferies Karuna Therapeutics Inc (NASDAQ: KRTX) ended nearly 50% up on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biopharmaceutical firm for $14 billion.
prnewswire.com ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc. NEW YORK , Dec. 22, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Karuna Therapeutics, Inc. (NASDAQ: KRTX) and its board of directors concerning the…
proactiveinvestors.com Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B deal Shares of biopharmaceutical company Karuna Therapeutics skyrocketed more than 47% Friday morning after giant Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) announced a deal to acquire the…
benzinga.com S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday? The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve’s favored…
investopedia.com Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook U.S. equities headed into the long holiday weekend with gains at midday, amid a broad-based rally fueled by enthusiasm over the possibility of several Fed interest rate cuts next year. The Dow, S&P…
investopedia.com Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal Karuna Therapeutics (KRTX) shares skyrocketed over 46% after Bristol Myers Squibb (BMY) said it would buy the biopharmaceutical firm for $14 billion to expand its neuroscience portfolio.
marketwatch.com Biotech stocks set for a rebound in 2024, analysts say A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.
prnewswire.com Shareholder Alert: Ademi LLP investigates whether Karuna Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol-Myers MILWAUKEE , Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Karuna (NASDAQ: KRTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol-Myers.…
cnbc.com Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.
24/7 Wall Street A Major Acquisition and Other News Ahead of the Holiday Weekend Before U.S. markets opened on Friday, the Bureau of Economic Analysis released its personal income and spending report for November.
investors.com Karuna Stock Soars On Bristol Myers' $14 Billion Takeover Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on Friday, sending KRTX stock into the stratosphere.
foxbusiness.com Bristol Myers to buy Karuna Therapeutics for $14B Karuna's crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.
benzinga.com Earnings Scheduled For November 2, 2023 Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
- benzinga.com Earnings Scheduled For August 3, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
- benzinga.com Earnings Scheduled For May 4, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 Upgrades
benzinga.com Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.- benzinga.com Nasdaq Turns Lower; Crude Oil Rises Over 1% U.S. stocks pared gains toward the end of trading, with the S&P 500 and the Nasdaq turning lower on Monday.
benzinga.com Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6…- benzinga.com Stocks That Hit 52-Week Highs On Tuesday On Tuesday, 596 companies set new 52-week highs.
- benzinga.com 52 Biggest Movers From Yesterday
- benzinga.com 36 Stocks Moving In Thursday's Mid-Day Session
benzinga.com 33 Stocks Moving In Wednesday's Mid-Day Session - benzinga.com 60 Biggest Movers From Yesterday
benzinga.com Stocks That Hit 52-Week Highs On Tuesday - benzinga.com Stocks That Hit 52-Week Lows On Monday
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday
- benzinga.com Stocks That Fell Through 52-Week Lows Wednesday
- benzinga.com Benzinga's Top Upgrades, Downgrades For July 23, 2019
- benzinga.com 48 Biggest Movers From Wednesday
- benzinga.com 33 Stocks Moving In Wednesday's Mid-Day Session